Foxp3 Expression in Liver Correlates with the Degree but Not the Cause of Inflammation
Table 2
Relative expression of the examined genes.
Gene
Normals
Chronic HBV hepatitis
Chronic HCV hepatitis
NAFLDb
Autoimmune diseasesc
MTX-related toxicityd
(no. 8)
Diagnosis (no. 19)
Relapse (no. 7)
(no. 14)
(no. 11)
(no. 8)
(no. 2)
Mean ± S.D.
Mean ± S.D. (P valuea)
Mean ± S.D. (P valuea)
Mean ± S.D. (P valuea)
Mean ± S.D. (P valuea)
Mean ± S.D. (P valuea)
Mean ± S.D.
Foxp3
1.11 ± 0.71
20.3 ± 16.0 (<.001)
10.4 ± 5.47 (.001)
12.7 ± 12.3 (.001)
18.4 ± 11.9 <.001
16.0 ± 15.2 (.001)
28.4 ± 27.8
TGF-β 1
1.56 ± 1.49
1.10 ± 0.84 (.710)
0.53 ± 0.31 (.053)
0.73 ± 0.58 (.065)
1.60 ± 1.01 (.620)
1.43 ± 1.04 (.834)
0.72 ± 0.17
IL-10
1.50 ± 1.02
0.66 ± 1.33 (.011)
0.20 ± 0.24 (.016)
0.48 ± 0.77 (.017)
0.79 ± 0.77 (.131)
0.64 ± 0.94 (.093)
0.59 ± 0.62
Fas
0.82 ± 0.24
2.25 ± 0.70 (<.001)
2.12 ± 0.78 (.003)
1.55 ± 1.07 (.179)
3.51 ± 1.17 (<.001)
1.56 ± 0.94 (.132)
4.14 ± 0.41
FasL
1.05 ± 1.47
4.20 ± 2.05 (.001)
3.05 ± 1.98 (.028)
4.20 ± 4.09 (.004)
3.94 ± 4.42 (.004)
4.33 ± 3.69 (.008)
0.49 ± 0.39
TRAIL
2.89 ± 2.04
7.28 ± 4.34 (.007)
11.3 ± 6.29 (.015)
8.86 ± 4.56 (.001)
15.3 ± 6.64 (<.001)
3.52 ± 2.11 (.355)
15.3 ± 12.7
Caspase-3
1.87 ± 1.85
1.13 ± 0.74 (.915)
0.76 ± 0.43 (.366)
1.66 ± 1.34 (.700)
1.97 ± 1.05 (.283)
3.19 ± 2.23 (.093)
2.28 ± 0.66
TNF-α
3.43 ± 4.70
1.77 ± 3.12 (.307)
1.54 ± 1.93 (.201)
2.73 ± 3.58 (.544)
8.17 ± 11.0 (.480)
6.63 ± 9.11 (.186)
1.21 ± 0.93
IFN-γ
1.92 ± 1.77
5.47 ± 5.99 (.202)
4.17 ± 2.46 (.186)
2.19 ± 1.77 (.628)
4.18 ± 4.93 (.572)
8.43 ± 7.25 (.059)
0.37 ± 0.26
IL-1β
1.37 ± 1.05
0.51 ± 1.39 (.022)
0.41 ± 0.66 (.055)
0.33 ± 0.26 (.042)
0.99 ± 0.95 (.322)
1.15 ± 1.12 (.571)
0.30 ± 0.23
aStatistical significance refers to comparison with the expression levels in the normal controls (Mann-Whitney U test); bNAFLD: nonalcoholic fatty liver disease; cautoimmune diseases group consists of 4 patients with autoimmune hepatitis and 4 with primary biliary cirrhosis; dMTX: methotrexate.
